Timeline
2013
Altratech founded
- Technology concept formulated, provisional patents filed.
- Equity seed-funding received.
2013
2014
Assay PNA probe and CMOS sensor component
- Assay PNA probe and CMOS sensor component operation demonstrated.
2014
2015
Altratech-NIH Relationship
- Altratech-NIH relationship established. Began lab testing of the higher performance cyclopentane PNA probes.
2015
2016
Investment
- PNA license agreement with NIH.
- A-round investment.
- EU H2020 SME Instrument Phase 1 award.
2016
2017
New AT102 CMOS chip
- New AT102 CMOS chip with 30-sensors taped-out. First silicon fully functional.
2017
2018
Grant Awarded
- EU H2020 SME Instrument phase 2 grant awarded, for HIV viral-load testing.
2018
2019
Patents Granted
- The first three key Altratech patents granted, in Europe and US.
2019
2020
SARS-CoV-2
Company focus switched to SARS-CoV-2 assay development.
2020
2021
Proof of Concept
- First proof-of-concept demonstration of end-to-end assay performance (in EU H2020 HIV project).
2021
2022
Publication
- Joint Altratech-NIH publication of ‘Keychain’ cyclopentane PNA joint-development, in Biopolymers (doi.org/10.1002/bip.23481).
- Publication of Altratech CMOS sensor in IEEE AACD (Springer, doi:10.1007/978-3-031-28912-5_6).
2022
2023
Awarded US -Gov Barda Feasibility Grant
- US-Gov Biomedical Advanced Research & Development Authority (BARDA) grant awarded to demonstrated PNA-probe tech-transfer from NIH to Altratech.
2023
2024
European Innovation Council Award
- Altratech receives European Innovation Council’s Accelerator Programme flagship Award to support HIV clinical trials.
2024
2025
Prototype at Tri-Con
Altratech exhibition and demonstrated its prototype at Tri-Con Molecular Conference, San Diego USA.
2025
2025
Gates Foundation Grant
- Gates Foundation grant received to support assay operation.
2025